Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.
Sec. Systems Endocrinology
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1464951
This article is part of the Research Topic Genetics and multi-omics approach in metabolic liver disorders View all 4 articles

Circulating irisin levels in patients with MAFLD: an updated systematic review and meta-analysis

Provisionally accepted
Chenglu Shen Chenglu Shen 1Kaihan Wu Kaihan Wu 1Yani Ke Yani Ke 2Zhang Qin Zhang Qin 1Shuaihang Chen Shuaihang Chen 3Qicong Li Qicong Li 1Yuting Ruan Yuting Ruan 1Xudan Yang Xudan Yang 1Shan Liu Shan Liu 4*Jie Hu Jie Hu 4*
  • 1 First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China
  • 2 School of Basic Medical Sciences and School of Public Health, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China
  • 3 Second Clinical Medical School, Zhejiang Chinese Medical University, Hangzhou, Jiangsu Province, China
  • 4 First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China

The final, formatted version of the article will be published soon.

    Current research suggests that irisin is closely linked to the pathogenesis and progression of metabolic dysfunction-associated fatty liver disease (MAFLD). This systematic review and meta-analysis updates our previous meta-analysis and further explores the relevance between circulating irisin levels and MAFLD.Nine databases (PubMed, EMBASE, Cochrane Library, CNKI, Wanfang, Weipu, CBM, Clinicaltrials.gov and gray literature) were retrieved as of 1 st August, 2024. The standardized mean difference (SMD) and 95% confidence interval (CI) represent pooled effect size. We used the Newcastle-Ottawa Scale to evaluate the quality of articles and the certainty of evidence assessed by GRADE system. All statistical analyses were performed using RevManRESULTS: Fifteen case-control studies were included. Circulating irisin levels in the MAFLD group were markedly lower than those in the healthy group (SMD=-1.04 [-1.93, -0.14]).Subgroup analyses by race, age, severity and T2DM revealed that circulating irisin levels were lower in the MAFLD group compared to those in the healthy controls in the Asian population (SMD=-1.38 [-2.44, -0.31], P<0.05) and in those above 50 years old (SMD=-2.23 [-3.64, -0.81], P<0.05) and higher in the mild MAFLD groups than those in moderate to severe MAFLD groups (SMD = 11.68 [9.05, 14.31], P<0.05). And the circulating irisin levels in MAFLD patients with T2DM were significantly lower than those in healthy group (SMD = -2.90 [-4.49, -1.30]). ELISA kits from different companies also presented different relationships.CONCLUSIONS: There were significantly lower circulating irisin levels in the MAFLD group than in the healthy control group. Although these results differed from our previous results, there is no denying that circulating irisin levels are closely associated with the advancement of MAFLD.

    Keywords: MAFLD, metabolic dysfunction-associated fatty liver disease, BMI, body mass index, CI, confidence interval, SD, standard deviation, SMD, standardized mean difference, NOS, Newcastle-Ottawa Quality Assessment Scale, PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses, NAFLD, non-alcoholic fatty liver disease

    Received: 15 Jul 2024; Accepted: 18 Nov 2024.

    Copyright: © 2024 Shen, Wu, Ke, Qin, Chen, Li, Ruan, Yang, Liu and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Shan Liu, First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310003, Zhejiang Province, China
    Jie Hu, First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310003, Zhejiang Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.